Oct 26, 2026
By Transpire Insight
Description
According to a research report published by Transpire Insight, the point-of-care Diagnostics market size is projected to grow from USD 16.15 billion in 2026 to USD 29.46 billion by 2035, at an 8.42% CAGR during the 2027-2035 forecast period. Rising chronic and infectious disease prevalence, an expanding geriatric population, decentralized healthcare demands, and advancements in microfluidics, biosensors, and digital AI connectivity are primary drivers of market growth.
Introduction
The Point-of-Care (POC) Diagnostics Market represents a critical paradigm shift in modern healthcare delivery, enabling rapid, actionable diagnostic testing at or near the site of patient care. By providing immediate results, POC testing bypasses time-consuming centralized laboratory processing, accelerating clinical decision-making and improving patient outcomes. Driven by advances in microfluidics, biosensors, and digital connectivity, the market spans applications in diabetes, cardiology, oncology, infectious diseases, and decentralized home care.
Recent Development News
January 2026: Abbott expanded its ID NOW point-of-care molecular testing platform with next-generation automated assays, significantly reducing turnaround times for respiratory panel detections in decentralized clinical environments.
May 2026: Roche Diagnostics announced regulatory clearance and commercial rollout for enhanced digital health integrations across its cobas liat POC molecular platform, enabling direct cloud-based electronic health record (EHR) synchronization.
Stay Ahead of Emerging Opportunities with Expert Market Insights by Transpire Insight
Transpire Insight provides comprehensive, data-driven market intelligence to support smarter business decisions. Our research is rooted in comprehensive analysis, authoritative predictions, and industry expertise, enabling organizations to make informed decisions in rapidly evolving markets. We provide in-depth analysis of market segmentation, competitive positioning, regional trends, and emerging investment opportunities in high-growth areas. We blend accuracy with actionable intelligence, helping companies uncover new growth avenues, strengthen strategic decision-making, and stay ahead in a dynamic market.
Point-of-Care Diagnostics Market Size & Statistics
The Market Size for Point-of-Care Diagnostics Was Estimated to be Worth USD 16.15 Billion in 2026.
The Market Size is Going to Expand at a CAGR of 8.42% between 2026 and 2035.
The Point-of-Care Diagnostics Market Size is anticipated to reach USD 29.46 Billion by 2035.
North America is projected to drive the highest demand during the forecast period, accounting for 46% of the point-of-care diagnostics market.
Asia-Pacific is projected to grow the fastest during the forecast period at a CAGR of 12.38% in the point-of-care diagnostics market.
Regional Growth and Demand Analysis by Transpire Insight
North America remains the largest regional market because of its advanced healthcare infrastructure, high diagnostic adoption, and dense base of leading manufacturers. Demand is supported by a heavy chronic disease burden, particularly diabetes and cardiovascular conditions. Broad reimbursement and CLIA-waiver pathways also let urgent care centers, pharmacies, and physician offices run tests on site. Recent product activity shows where the market is heading. Abbott’s i-STAT TBI whole blood test received FDA clearance as a handheld option for concussion assessment. Roche’s cobas liat system gained clearance and a CLIA waiver for its chlamydia, gonorrhea, and mycoplasma genitalium panel, bringing molecular-grade results to point-of-care sites.
Asia Pacific is the fastest-growing region, driven by rapid healthcare digitization, a rising burden of chronic and infectious diseases, and wider access to diagnostics in rural and underserved areas. Governments and domestic manufacturers are building local testing capacity, and India is a notable example. Cipla invested up to Rs 26 crore in Achira Labs, a point-of-care test kit developer, to support affordable decentralized testing. Telemedicine integration and mobile health solutions are also making it easier to deliver point-of-care diagnostics across the large, dispersed populations of China, India, and Southeast Asia.
Top 15 Trends in the Point-of-Care Diagnostics Market
Healthcare is moving diagnostics closer to patients, with pharmacies, clinics, and homes performing tests that once required laboratories, shortening turnaround times and improving patient access.
Compact PCR and isothermal amplification systems now deliver laboratory-grade sensitivity within minutes, driving hospitals and urgent care centers to adopt molecular testing at the bedside.
Machine learning algorithms help interpret test results, flag abnormal readings, and guide clinicians, reducing human error and enabling nonspecialist users to make faster treatment decisions.
Outbreaks of influenza, COVID-19, sexually transmitted infections, and tuberculosis sustain strong demand for quick, accurate tests, letting clinicians diagnose and treat patients during one visit.
Analyzers now transmit results to cloud platforms and electronic health records, improving data traceability, supporting remote monitoring, and helping health systems manage decentralized testing networks.
Manufacturers are shrinking analyzers into portable, battery-powered handheld formats that maintain accuracy, allowing paramedics, rural health workers, and patients to test outside conventional clinical settings.
List of Top 25 Companies in the Point-of-Care Diagnostics Market
1. Abbott Laboratories
leader in bedside diagnostic testing, infectious disease screening, and continuous glucose monitoring systems.
Founded: 1888 | HQ: Abbott Park, Illinois, USA.
Why It Ranks: Unrivaled distribution network and market-leading positions in glucose and infectious molecular POC.
Regional Dominance: Strongest presence in North America with massive penetration across European and Asian markets.
Product Line: FreeStyle Libre, ID NOW, i-STAT, BinaxNOW, Panbio rapid diagnostic test kits.
2. Roche Diagnostics
Pioneer in microfluidic PCR point-of-care instruments and decentralized clinical chemistry analyzers.
Founded: 1896 | HQ: Basel, Switzerland.
Why It Ranks: World-class molecular technology combined with robust hospital bedside diagnostic platforms.
Regional Dominance: Dominates the European market while holding significant market share across North America and APAC.
Product Line: cobas liat system, Accu-Chek series, CoaguChek, cobas h 232 POC analyzer.
3. Danaher Corporation (Cepheid)
Operates Cepheid, setting the gold standard for rapid molecular diagnostics globally.
Founded: 1984 | HQ: Washington, D.C., USA.
Why It Ranks: Market supremacy in automated molecular point-of-care PCR testing for infectious diseases.
Regional Dominance: Leading market position in North America alongside widespread adoption in Western Europe.
Product Line: GeneXpert Systems, Xpert Xpress assays, HemoCue blood diagnostic analyzers, Radiometer ABL.
4. Siemens Healthineers
Major innovator in handheld critical care testing, blood gas analysis, and urinalysis.
Founded: 1847 | HQ: Erlangen, Germany.
Why It Ranks: Industry-leading emergency care point-of-care systems integrated with enterprise hospital IT systems.
Regional Dominance: Strong market leadership across Europe and broad footprint in North America and Asia.
Product Line: epoc Blood Analysis System, DCA Vantage Analyzer, Clinitek Status, Atellica POC.
5. Becton, Dickinson and Company (BD)
Dominates rapid immunoassay testing for respiratory pathogens and point-of-care digital readers.
Founded: 1897 | HQ: Franklin Lakes, New Jersey, USA.
Why It Ranks: Extensive distribution in primary care, pharmacies, and urgent care clinics globally.
Regional Dominance: Leading footprint across North American health systems and expanding Asian clinical networks.
Product Line: BD Veritor System, BD MicroProbe, BD FACSPresto, rapid lateral flow test devices.
6. Thermo Fisher Scientific
Leading provider of specialty point-of-care diagnostics, biomarkers, and rapid clinical assays.
Founded: 1956 | HQ: Waltham, Massachusetts, USA.
Why It Ranks: Comprehensive portfolio covering critical care biomarkers, sepsis detection, and molecular reagent manufacturing.
Regional Dominance: Substantial market share in North America and major presence in European laboratories.
Product Line: Thermo Scientific B·R·A·H·M·S PCT, Phadia laboratory/POC immunodiagnostics, portable molecular kits.
7. bioMérieux
authority in infectious disease point-of-care testing and syndromic molecular diagnostic solutions.
Founded: 1963 | HQ: Marcy-l'Étoile, France.
Why It Ranks: Unmatched expertise in rapid syndromic testing for multiplex infectious disease clinical detection.
Regional Dominance: Major dominance in European healthcare markets with accelerating adoption in North America.
Product Line: BIOFIRE FILMARRAY Systems, VIDAS POC, SpotFire molecular point-of-care system, reagents.
8. QuidelOrtho Corporation
Formed through a high-profile merger, creating a powerhouse in rapid diagnostic devices.
Founded: 2022 (Merger) | HQ: San Diego, California, USA.
Why It Ranks: Massive market share in lateral flow testing and fluorescent immunoassay point-of-care systems.
Regional Dominance: Strong market presence across hospital and outpatient care networks in North America.
Product Line: Sofia 2 Analyzer, QuickVue rapid tests, Triage MeterPro, Ortho VITROS systems.
9. Nova Biomedical
leader in whole blood biosensor technology for critical care medical devices.
Founded: 1976 | HQ: Waltham, Massachusetts, USA.
Why It Ranks: Technology leadership in hospital blood gas, electrolyte, and critical care glucose platforms.
Regional Dominance: Dominates acute care and hospital ICU testing units in North America.
Product Line: StatStrip Glucose Monitor, Stat Profile Prime Plus blood gas analyzer, Allegro POC.
10. Sekisui Diagnostics
Premier manufacturer of rapid lateral flow point-of-care immunoassays and diagnostic enzymes.
Founded: 1981 | HQ: Burlington, Massachusetts, USA.
Why It Ranks: High reliability in rapid infectious disease testing across decentralized clinic settings.
Regional Dominance: Strong commercial presence in North America, Japan, and Western European diagnostic sectors.
Product Line: OSOM Rapid Tests, FastPack IP System, point-of-care infectious disease test kits.
Conclusion
The Point-of-Care Diagnostics Market is undergoing rapid expansion, catalyzed by decentralized healthcare demands, miniaturized molecular platforms, and artificial intelligence integration. Leading diagnostics players are continually improving diagnostic accuracy, reducing turnaround times, and broadening multiplex testing menus at the bedside. As home care monitoring and primary care early intervention gain momentum globally, point-of-care technologies will remain central to driving personalized medicine, lowering hospital strain, and elevating patient outcomes.
Send us a brief description of your challenge and we'll get back to you within 24 hours.
inquiry@transpireinsight.com
APAC:+91 7666513636
Address
